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Abstract
Purpose To investigate the effects of coadministration of
paroxetine or fluvoxamine on the pharmacokinetics of
aripiprazole in healthy adult Japanese with different
CYP2D6 genotypes.
Methods Fourteen CYP2D6 extensive metabolizer (EM) and
14 CYP2D6 intermediate metabolizer (IM) subjects were
coadministered a single oral dose of aripiprazole 3 mg after
steady-state plasma concentrations of the SSRIs paroxetine
(20 mg/day) or fluvoxamine (100 mg/day) were reached by
repeated oral doses for 6–7 days. The pharmacokinetics of
aripiprazole with and without coadministration ofSSRIs were
compared according to CYP2D6 genotypes.
Results Coadministration of paroxetine, a potent CYP2D6
inhibitor, decreased systemic clearance (CL/F) of aripiprazole
by 58 and 23% in CYP2D6 EMs and IMs, respectively,
demonstrating that the percentage inhibition of CYP2D6
activity by coadministration of paroxetine was apparently
greater in CYP2D6 EMs than in IMs. Coadministration of
fluvoxamine, a less potent CYP3A4 inhibitor, decreased the
CL/F of aripiprazole by 39% in CYP2D6 EMs and 40% in
IMs, indicating the same inhibitory effect on CYP enzymes,
regardless of the CYP2D6 genotype. Percent contribution of
CYP2D6 to total CL/F (CYP2D6 plus CYP3A4) of aripipra-
zole estimated as a reduced percentage of CL/F by CYP
enzyme inhibition was 62% for CYP2D6 EMs and 24% for
IMs in paroxetine coadministration, and 40% for CYP2D6
EMs and 18% for IMs in fluvoxamine coadministration.
Conclusions There were marked differences in the degree
of influence of paroxetine coadministration on the pharma-
cokinetics of aripiprazole between CYP2D6 EMs and IMs,
but no apparent differences were found between two
CYP2D6 genotypes in fluvoxamine coadministration. Ari-
piprazole can be used safely in combination with SSRIs
that have a CYP enzyme-inhibitory action.
Keywords Aripiprazole.CYP2D6 polymorphism.Drug
interaction.Fluvoxamine.Paroxetine.Pharmacokinetics
Introduction
Aripiprazole (APZ) is a novel atypical antipsychotic that
acts as a partial agonist at dopamine D2 receptors and the
serotonin 5-HT1A receptor, and as an antagonist at the
serotonin 5-HT2A receptor [1]. APZ is now widely used for
the treatment of schizophrenia in many countries worldwide
including the European Union, Japan, and the United
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Results of an in vitro metabolism study demonstrated
that APZ was metabolized only by human cytochrome
P450 isozymes CYP3A4 and CYP2D6 to dehydroaripipra-
zole (DAPZ; main metabolite in blood) and several other
metabolites, and DAPZ was also metabolized only by
CYP3A4 and CYP2D6 into several components, and those
metabolites are excreted in urine or feces. There was almost
no APZ or DAPZ excreted in urine and feces [2]. Because
of this metabolic fate of APZ, co-administration of APZ
with CYP3A4 or CYP2D6 inhibitors may potentially affect
the pharmacokinetics of APZ.
For the pharmacotherapy of schizophrenia, coadministra-
tion with antidepressants, mainly selective serotonin reuptake
inhibitors(SSRIs),hasbeenwidelyusedasadjunctivetherapy
depending on the patient’s symptoms. Additionally, coadmin-
istration of APZ with SSRIs is used as an adjunctive therapy
in patients with MDD. However, since many SSRIs have
inhibitory effects on the activities of hepatic CYP enzymes,
possible drug interactions caused by the combination of
SSRIs and other drugs have been of concern [3, 4].
Among the SSRIs, paroxetine (PRX) is a potent inhibitor
of CYP2D6 but has no inhibitory effect on the activities of
other CYP enzymes [5]. It has been reported that 93% of
CYP2D6 enzymes were inactivated at the steady-state
blood concentrations (35–43 ng/mL) of clinical doses of
PRX (20–30 mg q.d.) [6]. In contrast, fluvoxamine (FLV)
has been reported to be a less potent inhibitor but inhibits
both CYP3A4 and CYP2D6 [5, 7]. Moreover, FLV is
considered to potently inhibit CYP1A2 and CYP2C19 and
to mildly inhibit CYP3A4, CYP2C9, and CYP2D6.
However, the drug-drug interaction studies of the coadmin-
istration of FLV (100 mg q.d.) showed that FLV increased
the blood concentration of CYP3A4 substrates several-fold
[8–10], without significantly affecting the PK of desipra-
mine and metoprolol, both of which are CYP2D6 substrates
[11, 12], suggesting that FLV has an extremely weak or no
inhibitory effect on CYP2D6.
To date, two studies have been conducted to assess the
drug interaction of APZ with quinidine (CYP2D6 inhibi-
tor), and with ketoconazole and itraconazole (CYP3A4
inhibitors) in healthy subjects [2, 13].
Based on these findings, we investigated the effects of
coadministration of APZ and PRX or FLVon the pharmaco-
kinetics of APZ in healthy subjects. In addition, since DAPZ
has similar pharmacological activities as APZ, and both
CYP3A4 and CYP2D6 are involved in the generation and
elimination of DAPZ, we also investigated the pharmacoki-
netics of DAPZ [14]. CYP2D6 reportedly has genetic
polymorphisms that affect metabolic activity [15, 16]. Our
previous pharmacokinetic study of a single dose of 6 mg
APZ in healthy subjects demonstrated that the pharmacoki-
netics (PK) of APZ were different between CYP2D6
extensive metabolizer (EM) and intermediate metabolizer
(IM) subjects [17]. Similarly, it is considered that CYP2D6
polymorphism may affect the pharmacokinetics of APZ and
its main metabolite DAPZ. Thus, in this study, we performed
CYP2D6 genotyping and investigated the effects of coad-
ministration of APZ with SSRIs on the pharmacokinetics of
APZ and DAPZ according to CYP2D6 genotypes.
Methods
Study design and subjects
This study was designed as an open-label add-on study in
reference to the Guidance for Drug Interaction Studies
(notification no. 813 issued by the Pharmaceutical Affairs
Bureau, Ministry of Health, Labour and Welfare of Japan,
on June 4, 2001). The study was conducted in accordance
with the ethical principles that have their origins in the
Declaration of Helsinki, the Pharmaceutical Affairs Law,
and “Good Clinical Practice” (GCP). This study was
conducted with the approval of the ethics committee of
the clinical study institution.
Healthy Japanese male volunteers aged 20–40 years at
the time of informed consent with a body mass index (BMI)
ranging from 18.5 to 25.0 and with a CYP2D6 genotype
classified as EM or IM were eligible for the study.
Sample size was determined with reference to the results
of our previously published study [13]. Assuming that the
geometric mean ratios (GMR) for maximum concentration
(Cmax) and area under the curve (AUC)336h of APZ with
and without coadministration of SSRI were all 1.3, a
sample size of seven subjects per group would be enough to
provide 80% power to detect a difference between APZ
with and without coadministration of SSRI. Based on the
results of a screening test, seven eligible CYP2D6 EM
subjects and seven CYP2D6 IM subjects were randomly
selected from each PRX and FLV coadministration group
using a table of random numbers. A total of 28 subjects
(EM 14, IM 14) were selected.
The following subjects were excluded from the study:
those who were taking other medications; those who had
taken St. John’s wort products within 2 weeks prior to the
initial dose of the study drug; those who had taken grapefruit
and its processed products within 1 week prior to the initial
dose of the study drug; or those who had smoked within
1 month prior to the initial dose of the study drug.
Administration
APZ was administered as a single dose under fasting
conditions (period I), followed by a 34-day washout period.
30 Eur J Clin Pharmacol (2012) 68:29–37After the subjects were pretreated with PRX for 7 days or
FLV for 6 days, a single dose of APZ was coadministered
with PRX or FLV under fasting conditions at the steady-
state plasma concentration of these SSRIs, then repeated
oral doses of SSRIs were administered for 14 consecutive
days (period II) (Fig. 1).
One tablet containing 3 mg APZ (Abilify®, Otsuka
Pharmaceutical) was used for APZ administration. In the
PRX coadministration group, one tablet of PRX hydrochlo-
ride hydrate (Paxil Tablets® 20 mg, GlaxoSmithKline) was
administered once daily after breakfast. In the FLV coadmin-
istration group, one tablet of FLV maleate (Depromel®tablets
25 mg, Meiji Seika Kaisha) was administered for 3 days, and
subsequently two tablets were administered for 17 days as
repeated oral doses after breakfast and dinner (twice daily),
respectively. Subjects were admitted to the study site from the
day before APZ administration to day 4 of period I (5 days),
and from the day before SSRI administration in SSRI
pretreatment period to the day after completion of SSRI
administration in period II (22 or 23 days).
CYP2D6 genotyping
With the QIAamp DNA Blood Mini Kit (Qiagen, Tokyo,
Japan), DNAwas extracted from 2 mL of venous blood that
was collected using a blood collection tube containing
EDTA-2Na. To detect CYP2D6-mutated alleles, the Invader
method (for *2, *3, *4, *10, *14, *18, *21, *41) and the
Long-PCR method (for *5 gene-deleted) were performed.
Based on the results of CYP2D6 genotyping, the CYP2D6
genotypes of subjects were classified into three categories,
namely, PM (poor metabolizer: homozygotes with the non-
activity allele), IM (homozygotes with the deceased activity
allele), EM (homozygotes with the normal activity allele
and heterozygotes including the normal activity allele),
according to the Web site of CYP2D6 allele nomenclature
(http://www.cypalleles.ki.se/cyp2d6.htm).
The frequency of the PM genotype is generally reported
to be below 1% in the Japanese population [18–20].
Therefore, inclusion of an adequate number of PM subjects
in this study was considered to be difficult, and the study
was conducted with EM and IM subjects.
Drug concentration analysis and pharmacokinetic analysis
Venous bloodsampling(5mL)wasperformed at thefollowing
timesbothinperiodsIandII:within2hbeforeand1,2,3,4,5,
6, 8, 12, 24, 48, 72, 144, 240, and 336 h after APZ
administration. Each blood sample was collected using a
heparinized plasma separation tube and centrifuged for 10 min
(4°C, 1,581× g) to obtain the plasma. Plasma samples were
stored frozen at −20°C until assay. Plasma concentrations of
APZ and DAPZ were determined by liquid chromatography
tandem mass spectrometry (LC-MS/MS) [21]. The lower
limit of quantitation for both analytes was 0.1 ng/mL.
For the concentration range of 0.1–100 ng/mL, the intra-
assayprecisionwaslessthan5.1%CV(coefficientofvariation)
for APZ and less than 15.9% CV for DAPZ. The accuracy was
Period I
Period
6 5 3 4 2 4 6 3 5 3 2 1 y a D
APZ 3 mg 
a 3 mg 
b
PRX 
c
Period I
Period
Day 1 2 35 36 38 39 41 42 55
APZ 3 mg 
a 3 mg 
d
FLV 
e
I I d o i r e P t u o h s a W SSRI pre-treatment
Period II SSRI pre-treatment Washout
20 mg/day
50 mg/day 100 mg/day
a administration of aripiprazole (APZ) under fasting conditions 
b coadministration of APZ and paroxetine (PRX) under fasting conditions on Day 43 
c administration of PRX once daily after breakfast  
d coadministration of APZ and fluvoxamine (FLV) under fasting conditions in the morning on Day 42
e administration of FLV twice daily after breakfast and dinner 
Fig. 1 Dosing schedule
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DAPZ.
PK parameters of APZ [Cmax, AUC1, maximum concen-
tration time point (tmax ), elimination half life (t1/2,z), and
systemic clearance (CL/F )] and DAPZ (Cmax, AUC1,t max,
and t1/2,z) were calculated for each subject by a non-
compartmental method using the PK analysis software
WinNonlin Professional (version 5.2, Pharsight).
Statistical analysis
Descriptive statistics (mean and standard deviation) of the
plasma concentrations of APZ and DAPZ at each blood
drawing time point in periods I and II were determined for
CYP2D6 genotype of each coadministration group. In
addition, descriptive statistics of the PK parameters of
APZ and DAPZ in periods I and II were also calculated and
summarized for CYP2D6 genotype of each coadministra-
tion group. The values of GMR (period II/I) for PK
parameters (mean difference was calculated for tmax) were
also individually calculated and summarized for CYP2D6
genotype of each coadministration group.
Results
Summary of demographics at baseline
Of the 28 subjects treated in the study, 27 subjects,
excluding one subject who discontinued from the study in
period II, were included in the analysis of drug interaction.
The CYP2D6 genotypes in each coadministration group
were as follows: seven EM subjects (six for *1/*1 and one
for *1/*10) and seven IM subjects (six for *10/*10 and one
for *10/*21) in the PRX coadministration group; six EM
subjects (one for *1/*1, one for *1/*5, three for *1/*10, and
one for *1/*21) and seven IM subjects (one for *5/*10 and
six for *10/*10) in the FLV coadministration group.
The homozygote of CYP2D6 *1 allele was identified in
most of the EM subjects (six out of seven subjects) in the
PRX coadministration group, but only in one EM subject
(of seven) in the FLV coadministration group; thus an
incidental bias in the distribution of the CYP2D6 allele was
observed. There was no biased distribution of CYP2D6
allele in the IM subjects.
There were no marked differences in age, height, body
weight, and BMI between the coadministration groups or
between the EM and IM groups (Table 1).
Plasma concentration profiles
The time courses of the mean plasma concentrations of
APZ and DAPZ with and without PRX following a single
oral 3 mg dose of APZ in CYP2D6 EM and IM subjects are
shown in Fig. 2, and those for FLVare shown in Fig. 3. The
major PK parameters of APZ and DAPZ in terms of GMR
(period II/I) for these parameters are shown in Table 2
(PRX group) and Table 3 (FLV group).
PRX coadministration group
The tmax of APZ was approximately 3 h after a single dose
of APZ in period I and approximately 2 h after coadmin-
istration of APZ with PRX in period II. After that the
plasma APZ concentrations gradually decreased. The
plasma APZ concentrations of the EM subjects in the
terminal phase were consistently higher in period II than
in period I, while the plasma concentration-time profiles
of APZ in the IM subjects were similar in the two
periods.
Among the PK parameters of APZ in the EM subjects,
coadministration of PRX resulted in an increase in t1/2,z,a
58% decrease in CL/F, a 39% increase in Cmax, and a 140%
increase in AUC1. In the IM subjects, coadministration of
PRX resulted in a 23% decrease in CL/F, a 27% increase in
Cmax, and a 30% increase in AUC1, showing that the
effects of coadministration with PRX on the pharmacoki-
netics of APZ were smaller in the IM subjects than in the
EM subjects.
In addition, coadministration of PRX had no effect on
the plasma concentration-time profiles of DAPZ in the IM
subjects, whereas in the EM subjects, the Cmax of DAPZ
was decreased as opposed to the result obtained in APZ, the
t1/2,z was increased similarly to the result obtained in APZ.
The plasma concentration-time profiles of DAPZ in period
II were similar between the EM and IM subjects.
FLV coadministration group
The plasma APZ concentration reached its maximum
approximately 2–3 h after a single dose of APZ both in
period I and period II and then remained at a higher level in
period II than in period I in both the EM and IM subjects.
The values of GMR (period II/I) for PK parameters of
APZ were comparable between the IM and EM subjects.
Compared with period I (administration of APZ alone), the
CL/F of APZ was decreased by approximately 40%, and
the AUC1 was increased by approximately 60% in period
II in both the IM and EM subjects.
Coadministration of FLV increased both Cmax and t1/2,z of
DAPZ in the EM subjects. The results were similar to those
observed in APZ. In contrast, in the IM subjects, no
apparent changes were found in the plasma concentration-
time profiles of DAPZ because of an inability to detect the
elimination phase of DAPZ in period II in these IM
subjects.
32 Eur J Clin Pharmacol (2012) 68:29–37Calculations of the contribution of CYP enzyme to APZ
metabolism
In this study, we investigated the changes in the PK
parameters of APZ and its main metabolite DAPZ accord-
ing to CYP2D6 genotypes after administration of APZ
alone and after coadministration with clinical doses of
SSRIs.
The changes in CL/F, one of the parameters to indicate
the metabolic activities of hepatic CYP enzymes, before
and after coadministration of PRX or FLV, are shown in
Fig. 4.
The extent of change in the CL/F after coadministration
of PRX (a potent CYP2D6 inhibitor) was comparable
between the EM and the IM subjects. In contrast,
coadministration of FLV, a less potent CYP3A4 inhibitor,
showed no such marked difference in the extent of decrease
in the CL/F between CYP2D6 EM and IM subjects.
Considering that most APZ disappeared from the body
by the metabolism via liver CYP enzymes (CYP2D6 and
CYP3A4), we calculated the contribution of CYP2D6 and
CYP3A4 to the hepatic metabolism of APZ expressed as
CL/F, based on the assumptions as follows:
1. Coadministration of APZ and PRX inhibits the meta-
bolic activity of CYP2D6 by 93% (i.e., the amount of
reduced CL/F by coadministration of PRX is equivalent
to 93% of CL/F corresponding to the CYP2D6 [6]).
2. Coadministration of FLV inhibits the metabolic activity
of CYP3A4 by a similar percentage in all subjects
regardless of their CYP2D6 genotype.
3. Mean CL/F values corresponding to the CYP3A4 for
EM and IM subjects after administration of APZ alone
(before coadministration of FLV) in the FLV coadmin-
istration group are similar to those in the PRX
coadministration group.
As a result, in terms of CYP3A4, the mean CL/F value
calculated from the amount of reduced CL/F by coadminis-
tration of PRX was 1.98 L/h for CYP2D6 EM subjects and
1.74 L/h for CYP2D6 IM subjects. If the mean CL/F values
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Fig. 2 Time courses of plasma
concentrations of aripiprazole
(APZ) and dehydroaripiprazole
(DAPZ) in CYP2D6 EMs and
IMs with and without paroxetine
(PRX) following a single oral
dose of 3 mg APZ (mean+
standard deviation, semiloga-
rithmic scale). Figure at the top
right is shows the 0–24 h
plasma concentrations of APZ
(mean+standard deviation,
actual scale). EM Extensive
metabolizer, IM intermediate
metabolizer
Group Paroxetine coadministration Fluvoxamine coadministration
CYP2D6 genotype EM (n=7) IM (n=7) EM (n=6) IM (n=7)
Age (years) 28.9±4.8 32.1±6.1 25.0±4.0 25.4±2.2
Height (cm) 175±5 173±6 174±4 170±6
Weight (kg) 69.7±6.3 67.1±7.7 65.9±6.5 64.0±8.3
BMI 22.7±1.3 22.5±1.9 21.7±1.7 22.1±1.8
Table 1 Demographic character-
istics of subjects included in the
drug interaction analysis (n=27)
Values are mean±standard
deviation
EM Extensive metabolizer, IM
intermediate metabolizer
Eur J Clin Pharmacol (2012) 68:29–37 33corresponding to CYP3A4 for the EM and IM subjects in the
FLV coadministration group are equal to those in the PRX
coadministration group, the percent inhibition of CYP3A4 by
coadministration of FLV was calculated to be 64% for
CYP2D6 EM subjects and 48% for CYP2D6 IM subjects.
Estimated values of CL/F (mean and standard deviation)
related to CYP2D6 and CYP3A4 for each subject,
calculated according to the above-mentioned assumptions
and procedure, for each SSRI coadministration group are
shown in Fig. 5. The percent contribution of CYP2D6 to
total metabolic activity of APZ before the inhibition of
CYP enzymes by the SSRIs was calculated to be 62 and
24% in the EM and IM subjects of the PRX coadministra-
tion group, respectively, and 40 and 18% in the EM and IM
subjects of the FLV coadministration group, respectively.
Discussion
APZ is mainly metabolized into its main metabolite, DAPZ,
by CYP3A4 and CYP2D6 [2], both of which are involved in
the generation and elimination of DAPZ [14]. CYP2D6
exhibits extensive genetic polymorphism. More than 20
CYP2D6 alleles have been identified in Japanese subjects
[22, 23], many of which are reported to show reduced
activity or a loss of activity that may affect drug pharmaco-
kinetics. Racial differences in the frequency of each
genotype have also been reported.
It has also been reported that there is large individual
variability in CYP3A4 metabolic activity due to differences
in the amount of enzymatic protein, although no genetic
polymorphism of CYP3A4 has been found that affects its
metabolic activity [24]. For APZ metabolism, the intensity
of metabolic activities of CYP3A4 and CYP2D6 corre-
sponds to the amount of systemic clearance (CL/F).
DAPZ exposure in blood (AUC) following repeated
administration at clinical levels was about 25% of that of
APZ [25], regardless of CYP2D6 genotype. It was
considered that the change in the AUC of DAPZ by SSRI
coadministration would have little influence on overall
exposure (APZ plus DAPZ) and the efficacy and safety of
APZ. Therefore, this study mainly investigated the influ-
ence of SSRI coadministration on the CL/F of APZ.
In the present study, the large interindividual variability
in CL/F (23% CV) observed in the EM subjects of PRX
coadministration group was reduced (14% CV) by coad-
ministration of PRX due to nearly complete inhibition of
CYP2D6. However, in the IM subjects, the interindividual
variability in CL/F (14% CV) was much smaller compared
to the EM subjects and did not differ greatly from that (11%
CV) after coadministration of PRX. Both the CL/F values
and the interindividual variability after coadministration of
PRX were similar in CYP2D6 EM and IM subjects. In
contrast, all the EM subjects in the FLV coadministration
group showed a similar decrease in CL/F after coadminis-
tration of FLV; no change in interindividual variability was
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Eur J Clin Pharmacol (2012) 68:29–37 35found after coadministration of FLV. Similar results were
obtained in the IM subjects (see Fig. 4).
It is assumed that most of the reduced CL/F due to
coadministration of PRX is equivalent to the decrease in
CL/F of CYP2D6, and the remainder represents the CL/F of
CYP3A4 alone. Moreover, most of the reduced CL/F by
coadministration of FLV is equivalent to the decrease in
CL/F of CYP3A4.
These findings suggest that the relatively large interin-
dividual variability in CL/F of APZ found in the EM
subjects within the PRX and FLV coadministration groups
was mainly attributable to the interindividual variability in
CYP2D6 enzyme activity accompanied by the incidentally
biased distribution of CYP2D6 diplotype in this study.
Additionally, interindividual variability in CL/F of CYP3A4
in healthy subjects is presumed to be comparatively small.
However, since the decrease in CL/F of APZ by
coadministration of FLV was comparable between CYP2D6
EM and IM subjects, the possibility that FLV may
potentially inhibit CYP2D6 to some extent cannot be
excluded.
The changes in the PK parameters of APZ by coadmin-
istration of PRX or FLV found in this study were similar to
the following results previously reported in drug interaction
studies: coadministration of APZ 10 mg with the CYP2D6
inhibitor quinidine 166 mg increased AUC1 of APZ by
112% and decreased AUC1 of DAPZ by 35% [2],
coadministration of APZ 15 mg with the CYP3A4 inhibitor
ketoconazole 200 mg increased AUC1 of APZ and DAPZ
by 63 and 77%, respectively, in American subjects [2], and
coadministration of APZ 3 mg with the CYP3A4 inhibitor
itraconazole 100 mg decreased CL/F of APZ by 27 and
47% in Japanese EM and IM subjects, respectively [13].
Since the increase in blood exposure (APZ+DAPZ) after
coadministration with SSRI was around three times at the
maximum in both CYP2D6 EM and IM subjects, it was
considered that APZ can be used safely in combination
with SSRIs.
In conclusion, this study demonstrated that there were
marked differences in the degree of influence on the
pharmacokinetics of APZ by coadministration of PRX
between CYP2D6 EM and IM genotypes, whereas these
differences during FLV coadministration were small and
almost negligible.
The percent contribution of enzymes CYP2D6 and
CYP3A4 to the CL/F (i.e., metabolic activity) for APZ in each
subject was calculated, assuming both the percent inhibition of
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CYP2D6 IM
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Fig. 4 Changes in systemic
clearance of aripiprazole (APZ)
by coadministration of clinical
doses of paroxetine (PRX) and
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(EM) and intermediate
metabolizers (IM) are shown,
respectively, with solid lines and
dashed lines
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Fig. 5 Change in the estimated systemic clearance (CL/F) of
aripiprazole (APZ) by CYP enzyme inhibition after coadministration
with SSRIs. The error bars represent the standard deviation of
CYP2D6 (lower), CYP3A4 (middle) and the total (upper). EM
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36 Eur J Clin Pharmacol (2012) 68:29–37CYP2D6 by coadministration of PRX and the percent
inhibition of CYP3A4 by coadministration of FLVare constant.
Our findings suggest that the percent contribution of
CYP enzymes to the metabolic activity for APZ can be
estimated, and the pharmacokinetic behavior of each CYP
genotype can definitely be presumed by inhibiting the
metabolic enzymes of APZ with SSRIs.
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